pegozafermin

News

Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its phase 3 candidate pegozafermin for MASH.

Oncology

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.